Quattro Financial Advisors LLC Has $1.21 Million Stake in Pfizer Inc. $PFE

Quattro Financial Advisors LLC decreased its stake in Pfizer Inc. (NYSE:PFE) by 33.3% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,000 shares of the biopharmaceutical company’s stock after selling 25,000 shares during the quarter. Quattro Financial Advisors LLC’s holdings in Pfizer were worth $1,212,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Bessemer Group Inc. boosted its stake in Pfizer by 11.1% in the 1st quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company’s stock valued at $3,358,000 after buying an additional 13,228 shares in the last quarter. Capital Advisors Inc. OK boosted its stake in Pfizer by 1.2% in the 1st quarter. Capital Advisors Inc. OK now owns 1,413,472 shares of the biopharmaceutical company’s stock valued at $35,817,000 after buying an additional 17,032 shares in the last quarter. CHURCHILL MANAGEMENT Corp acquired a new position in Pfizer in the first quarter worth $8,283,000. Westbourne Investments Inc. acquired a new position in Pfizer in the first quarter worth $2,411,000. Finally, Bourne Lent Asset Management Inc. boosted its stake in Pfizer by 90.8% in the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company’s stock worth $927,000 after purchasing an additional 18,200 shares in the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

PFE has been the topic of a number of recent analyst reports. Morgan Stanley boosted their price objective on Pfizer from $32.00 to $33.00 and gave the stock an “equal weight” rating in a research note on Wednesday, August 6th. Citigroup boosted their price objective on Pfizer from $25.00 to $26.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Wall Street Zen lowered Pfizer from a “buy” rating to a “hold” rating in a research note on Sunday, September 28th. UBS Group reissued a “neutral” rating and issued a $28.00 price objective on shares of Pfizer in a research note on Wednesday. Finally, Bank of America boosted their price objective on Pfizer from $27.00 to $28.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has a consensus rating of “Hold” and an average target price of $28.29.

Pfizer Trading Down 0.5%

PFE stock opened at $27.08 on Friday. The company has a market cap of $153.94 billion, a P/E ratio of 14.40, a PEG ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business has a fifty day moving average of $24.62 and a 200-day moving average of $24.14.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, topping analysts’ consensus estimates of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The firm’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.